Britain's GSK racks a $163m stake in Germany's CureVac | FI SENSE


Britain’s GSK said on Monday it would invest  $163 million to buy a 10% stake in Germany’s CureVac, launching a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine.

CureVac’s existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said.

CureVac said in June it would start human trials of an experimental vaccine for treating COVID-19 in the country.

The company, based in Tuebingen and backed by the Bill & Melinda Gates Foundation, is using the so-called messenger RNA approach that has also been adopted by BioNTech and its partner Pfizer as well as Moderna.



Leave a Reply

Your email address will not be published. Required fields are marked *

FI Sense